



Paris NASH Meeting

July 11 & 12, 2019

Institut Pasteur

5th edition

Organized by

Arun Sanyal

Virginia Commonwealth
University School of Medicine,
Richmond, Virginia, USA

Lawrence Serfaty

Hôpital Hautepierre
Hôpitaux Universitaires
de Strasbourg, France

Scientific committee

Quentin Anstee
Pierre Bedossa
Laurent Castera
Jean-François Dufour
Scott Friedman
Fabio Marra
Philippe Mathurin
Veronica Miller
Frank Tacke
Michael Trauner



With the partnership of





International Think Tank

Paris NASH Meeting

July 11 & 12, 2019, Paris **SCIENTIFIC PROGRAM**

International Think Tank

THURSDAY, JULY 11, 2019

08:00 - 08:30 am

CONFERENCE OPENING

08:30 - 08:35 am

Welcome remarks - Lawrence Serfaty (France)

08:35 - 08:45 am

Inauguration Address - Director Institut Pasteur

08:45 - 10:00 am

SESSION 1 • PUBLIC HEALTH AND POLICY

Chairs: Patrick Marcellin (France) and Michael Trauner (Austria)

08:45 - 09:00 am

Are the estimates of burden of disease real-fact checking the validity of current models?

Homie Razavi (USA)

09:00 - 09:15 am

European perspectives on NASH - experience from the Constances cohort.

Lawrence Serfaty (France)

09:15 - 09:30 am

**The metrics of the value of NASH interventions for patients and payers.
The CoreNASH project update.**

Elizabeth Clearfield (USA)

09:30 - 10:00 am

Discussion

10:00 - 10:30 am

COFFEE BREAK AND POSTERS

10:30 - 12:00 am

SESSION 2 • MODIFIABLE DRIVERS OF DISEASE PROGRESSION

Chairs: Fabio Marra (Italy) and Lawrence Serfaty (France)

10:30 - 10:45 am

Can novel genetic markers be leveraged for therapeutics?

Quentin Anstee (United Kingdom)

10:45 - 11:00 am

Addiction behavior, depression and other behavioral barriers to successful lifestyle intervention.

Gerard Moeller (USA)

11:00 - 11:15 am

Is alcohol a modulator of disease progression in NASH?

Phillippe Mathurin (France)

11:15 - 11:30 am

Socio-economic and family-based risk factors as drivers of disease severity and outcomes of lifestyle interventions.

Mary Rinella (USA)

11:30 - 12:00 pm

Discussion



Paris
NASH
Meeting

July 11 & 12, 2019, Paris
SCIENTIFIC PROGRAM

International Think Tank

12:00 - 12:30 pm

STATE OF THE ART LECTURE

Chair: Arun Sanyal (USA)

The role of the adipocyte in the genesis of NAFLD and NASH
Philipp Scherer (USA)

12:30 - 02:00 pm

LUNCH BREAK

02:00 - 03:30 pm

SESSION 3 • CLINICAL ASPECTS OF NAFLD

Chairs: Philippe Mathurin (France) and Lawrence Serfaty (France)

02:00 - 02:20 pm

Controversy: is NAFLD a driver or simple marker of cardiovascular risk?
Franck Boccara (France) vs Fabio Marra (Italy)

02:20 - 02:35 pm

Is the WHO definition of cirrhosis still relevant in the age of NASH-lessons learned about the evolution of advanced fibrosis in NASH?
Pierre Bedossa (France)

02:35 - 02:50 pm

Implications of NASH as the etiology of cirrhosis in the context of liver transplantation.
Mohammad Shadab Siddiqui (USA)

02:50 - 03:05 pm

Familial NAFLD and the risk of fibrosis.
Cyrielle Caussy (France)

03:05 - 03:30 pm

Discussion

03:30 - 04:00 pm

COFFEE BREAK AND POSTERS

04:00 - 05:30 pm

SESSION 4 • TECHNOLOGIC INNOVATIONS IN NASH

Chairs: Laurent Castera (France) and Frank Tacke (Germany)

04:00 - 04:15 pm

Microparticles in disease progression in NASH and their potential utility as diagnostic and predictive biomarkers.
Pierre-Emmanuel Rautou (France)

04:15 - 04:30 pm

The ability to predict histological response from MR parameters-lessons learned from phase 2 trials.
Michael Middleton (USA)

04:30 - 04:45 pm

Using technology for care delivery and improving outcomes.
Giulio Marchesini (Italy)

04:45 - 05:00 pm

Liver tissue engineering: where are we now?
Massimo Pinzani (United Kingdom)

05:00 - 05:30 pm

Discussion

05:30 - 05:45 pm

POSTER AWARD



Paris
NASH
Meeting

July 11 & 12, 2019, Paris
SCIENTIFIC PROGRAM

International Think Tank

FRIDAY, JULY 12, 2019

07:45 - 08:00 am

WELCOME DESK OPENING

08:00 - 09:30 am

SESSION 5 • DIAGNOSTICS

Chairs: Quentin Anstee (United Kingdom) and Pierre Bedossa (France)

08:00 - 08:15 am

How to evaluate the patient with suspected NASH in clinic using currently available tools?

Jean-François Dufour (Switzerland)

08:15 - 08:30 am

A deep-dive into elastography: does methodology matter?

Laurent Castera (France)

08:30 - 08:45 am

Use of proteomics in the assessment of disease activity and stage in NASH.

Yi Luo (USA)

08:45 - 09:00 am

How to improve screening for clinical trials and treatment indication?

Jérôme Boursier (France)

09:00 - 09:30 am

Discussion

09:30 - 10:00 am

COFFEE BREAK

10:00 - 11:30 am

SESSION 6 • ADVANCES IN NASH PHARMACOLOGY

Chairs: Jean-François Dufour (Switzerland) and Arun Sanyal (USA)

10:00 - 10:15 am

Potential use of glucose-lowering drugs (GLP-1 and SGLT2 inhibitors) in NASH.

Michael Roden (Germany)

10:15 - 10:30 am

PPAR biology beyond thiazolidinediones and novel applications for NASH.

Bart Staels (France)

10:30 - 10:45 am

Mitochondrial uncoupling as a target for NASH therapeutics.

Gerald Shulman (USA)

10:45 - 11:00 am

Similarities and differences between classical FXR agonists versus non-steroidal agents.

Michael Trauner (Austria)

11:00 - 11:30 am

Discussion

11:30 - 12:00 pm

**SPECIAL LECTURE: PURSUING THE HOLY GRAIL OF
PRECISION MEDICINE FOR NASH.**

Chair: Arun Sanyal (USA)



Paris NASH Meeting

July 11 & 12, 2019, Paris
SCIENTIFIC PROGRAM

International Think Tank

12:00 - 02:00 pm LUNCH BREAKOUT SESSION

- GROUP 1:** **Review of recent clinical trials of NASH.**
Raluca Pais (France) and Mary Rinella (USA)
- GROUP 2:** **Progress in development of combination therapeutics.**
Frank Tacke (Germany) and Michael Trauner (Austria)
- GROUP 3:** **Managing Cardiometabolic disease and risk in NAFLD.**
Michael Roden (Germany) and Mohammad Shadab Siddiqui (USA)
- GROUP 4:** **Best approach for diagnosis and triage of NASH in the diabetes clinic.**
Bertrand Cariou (France) and Laurent Castera (France)

02:00 - 02:30 pm SESSION 7 • REGULATORY UPDATE

Chair: Lawrence Serfaty (France)

Veronica Miller (USA)

02:30 - 04:00 pm SESSION 8 • INDUSTRY SPONSORED SESSION

Chairs: Arun Sanyal (USA) and Lawrence Serfaty (France)

- | | | |
|------------------|---------------------------------|-----------------------------|
| 02:30 - 02:40 pm | GILEAD SCIENCES SESSION | Kathryn Kersey |
| 02:40 - 02:50 pm | INTERCEPT PHARMA SESSION | Aldo Trylesinski |
| 02:50 - 03:00 pm | PFIZER SESSION | Fady Ntanios |
| 03:00 - 03:10 pm | ALLERGAN SESSION | Eduardo Bruno Martins |
| 03:10 - 03:20 pm | GENFIT SESSION | To be confirmed |
| 03:20 - 03:30 pm | NOVARTIS SESSION | Clifford Brass |
| 03:30 - 03:40 pm | MSD SESSION | Sam Engel or Eirum Chaudhri |
| 03:40 - 04:00 pm | Discussion | |

04:00 pm **Concluding remarks**



International Think Tank

Paris
NASH
Meeting

July 11 & 12, 2019, Paris
SCIENTIFIC PROGRAM

International Think Tank

FACULTY 2019

ANSTEE Quentin

BEDOSSA Pierre

BOCCARA Franck

BOURSIER Jérôme

CARIOU Bertrand

CASTERA Laurent

CAUSSY Cyrielle

CLEARFIELD Elizabeth

DUFOUR Jean-François

LUO Yi

MARCELLIN Patrick

MARCHESINI Giulio

MARRA Fabio

MATHURIN Philippe

MIDDLETON Michael

MILLER Veronica

MOELLER Gerard

PAIS Raluca

PINZANI Massimo

RAUTOU Pierre-Emmanuel

RAZAVI Homie

RINELLA Mary

RODEN Michael

SANYAL Arun

SCHERER Philipp

SERFATY Lawrence

SHULMAN Gerald

SIDDIQUI Mohammad Shadab

STAELS Bart

TACKE Frank

TRAUNER Michael

July 11 & 12, 2019, Paris

INSTITUT PASTEUR

28 Rue du Docteur Roux
75015 PARIS • FRANCE

Congress Secretariat

TAMING HEALTHCARE

58, Bd de la République
92100 Boulogne-Billancourt
+33 1 84 20 32 30

Contact:

contact@paris-nash.org

www.paris-nash.org



International Think Tank

Paris
NASH
Meeting